(A-136) Comparison Of Tamsulosin And Dutasteride Combination Versus Silodosin And Dutasteride Combination In Patients With Benign Prostatic Hyperplasia

Background: Benign Prostatic Hyperplasia (BPH) significantly contributes to lower urinary tract symptoms
(LUTS), adversely affecting quality of life (QoL). This study aims to compare symptomatic
improvement and QoL in patients receiving Silodosin and Dutasteride versus Tamsulosin and
Dutasteride, utilizing the International Prostate Symptom Score (IPSS) and IPSS QoL score.

Objectives: To determine symptomatic
improvement and QoL in patients receiving Silodosin and Dutasteride versus Tamsulosin and
Dutasteride, utilizing the International Prostate Symptom Score (IPSS) and IPSS QoL score

Methods: A prospective observational study was conducted at the outpatient department of Urology,
Government Medical College, Kozhikode, over six months with institutional ethics approval.
Patients were assigned to receive either Silodosin 8 mg + Dutasteride 0.5 mg or Tamsulosin 0.4
mg + Dutasteride 0.5 mg. Symptomatic improvement and QoL were assessed using the IPSS and
IPSS QoL questionnaire. Uroflowmetric data, including Qmax and Qave, were collected. Adverse
drug events were monitored. Data analysis was performed using SPSS, with p < 0.05 considered
statistically significant

Results: Ninety-seven subjects were enrolled: 46 on Tamsulosin + Dutasteride and 51 on Silodosin +
Dutasteride. Significant reductions in IPSS scores and improvements in QoL were observed in the
Silodosin group compared to the Tamsulosin group (p < 0.05). Both groups showed comparable
improvements in Qmax and Qave. Both treatment combinations exhibited high tolerability, with
mild adverse effects such as dizziness, postural hypotension, and ejaculation disorders reported
infrequently.

Conclusions: Silodosin combined with Dutasteride is more effective than Tamsulosin combined with
Dutasteride in reducing IPSS scores and enhancing QoL over six months. Both regimens
demonstrated comparable efficacy in improving urinary flow rates, with a favorable safety profile.